Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold

TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that it has filed a supplement (the “Supplement”) to its management information circular dated September 28, 2026 (the “Circular”) in connection with the annual general and special meeting of shareholders of the Company scheduled for November 10, 2026 at 1:00 p.m. (Eastern time) (the “Meeting”).

The Supplement corrects and restates the special resolution to be considered at the Meeting authorizing a consolidation of the Company’s class A multiple voting shares (the “MVS”) and class B subordinate voting shares (the “Class B Subordinate Voting Shares”). The correction clarifies the treatment of fractional shares resulting from the consolidation. If the consolidation would otherwise result in a fractional MVS or Class B Subordinate Voting Share, any fraction equal to or less than one-half of a share will be rounded down to the nearest whole share, and any fraction greater than one-half of a share will be rounded up to the nearest whole share.